988 Results

People

  1. Lesokhin
    Lesokhin
  2. Landgren
    Landgren
  3. Hassoun
    Hassoun
  4. Mailankody
    Mailankody
  5. Landau
    Landau
  6. Giralt
    Giralt
  7. Korde
    Korde
  8. Hultcrantz
    Hultcrantz
  9. Chung
    Chung
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)
  7. Sloan Kettering Institute Postdocs (292)
  8. Bone Marrow Transplant (289)
  9. Epidemiology and Biostatistics (209)
  10. Biostatistics Service (175)
  1. "Myeloma"
Formats
  1. Meeting Abstract (543)
  2. Journal Article (358)
  3. Review (36)
  4. Research Letter (19)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)

More Groups

People
  1. Alexander Lesokhin (363)
  2. Carl Landgren (336)
  3. Hani Hassoun (329)
  4. Sham Mailankody (282)
  5. Malin Hultcrantz (260)
  6. Heather Landau (239)

More People

Years
  1. 2025 (13)
  2. 2024 (69)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (303)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (22)

More Publications

Publishers
  1. American Society of Hematology (324)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (83)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (988)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study
    Meeting Abstract

    Patel, K.; Zonder, J. A.; Sano, D.; Maris, M.; Lesokhin, A.; von Keudell, G.; Lai, C.; Ramchandren, R.; Catalano, T.; Lin, G. H. Y.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Updated results from CARTITUDE-1: Phase 1b/2study of ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Martin, T.; Usmani, S. Z.; Berdeja, J. G.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Hari, P.; Avigan, D.; Deol, A.; Htut, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Liedtke, M.; Sidana, S.; Matous, J. V.; Chhabra, S.; Oluwole, O. O.; Malik, S. A.; Kumar, S.; Nath, R.; Anwer, F.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Defining new reference intervals for serum free light chains in individuals with reduced kidney function: Results of the population- based on Iceland screens treats or prevents multiple myeloma (iStopMM) study
    Meeting Abstract

    Long, T. E.; Indridason, O. S.; Palsson, R.; Rögnvaldsson, S.; Love, T. J.; Thorsteinsdottir, S.; Sverrisdottir, I. S.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The genomic landscape of Waldenström Macroglobulinemia reveals sustained germinal center activity and late-developing copy number aberrations
    Meeting Abstract

    Maclachlan, K. H.; Bagratuni, T.; Kastritis, E.; Ziccheddu, B.; Lu, S. X.; Yellapantula, V. D.; Famulare, C.; Diamond, B.; Chojnacka, M.; Raj, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Magnetismm-3: An open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Lesokhin, A.; Iida, S.; Stevens, D.; Gabayan, A. E.; Ma, W. D.; Sullivan, S.; Raab, M. S.
    Blood (2021)

    Fulltext@MSK | Save
  • Screening for monoclonal gammopathy of undetermined significance: A population-based randomized clinical trial. First results from the Iceland screens, treats, or prevents multiple myeloma (iStopMM) study
    Meeting Abstract

    Kristinsson, S. Y.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Reed, E. R.; Oskarsson, J. T. T.; Petursdottir, I.; Sigurdardottir, G. A.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R. C.; Brunner, J.; Byrne, J.; Eliason, L.; more...
    Blood (2021)

    Fulltext@MSK | Save